Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial

By sjmartinez • July 20, 2024

Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM; ACTIV-2/A5401 Study Team. Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. J Infect Dis. 2024 Jul 20:jiae369. doi: 10.1093/infdis/jiae369. Epub ahead of print. PMID: 39028902.

Tags: ACTIV-2, casirivimab/imdevimab, Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, outpatient treatment, polyclonal antibodies, Publications, SAB-185, transchromosomic

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]

Hypokalemic periodic paralysis presenting as cardiac arrest

Joshi M, Salameh W, Vintch J, Goodman EL. Hypokalemic periodic paralysis presenting as cardiac arrest. BMJ Case Rep. 2024 Nov 13;17(11):e259889. doi: 10.1136/bcr-2024-259889. PMID: 39537393.

Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Chien C, Cruz E Silva V, Geiter E, Meier D, Zimmermann H, Bichuetti DB, Idagawa MI, Altintas A, Tanriverdi U, Siritho S, Pandit L, Dcunha[...]